|
Innovent Biologics, Inc. (1801.HK) DCF -Bewertung
CN | Healthcare | Biotechnology | HKSE
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Innovent Biologics, Inc. (1801.HK) Bundle
Möchten Sie den inneren Wert von Innovent Biologics, Inc. bewerten? Unser (1801HK) DCF-Taschenrechner integriert reale Daten mit umfassenden Anpassungsfunktionen, sodass Sie Ihre Prognosen verfeinern und Ihre Anlagestrategien verbessern können.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,118.8 | 4,105.5 | 4,560.4 | 4,866.6 | 6,628.6 | 9,180.6 | 12,715.1 | 17,610.4 | 24,390.4 | 33,780.8 |
| Revenue Growth, % | 0 | 266.94 | 11.08 | 6.71 | 36.21 | 38.5 | 38.5 | 38.5 | 38.5 | 38.5 |
| EBITDA | -1,681.3 | -752.7 | -2,536.2 | -1,868.4 | -705.7 | -4,094.3 | -5,670.6 | -7,853.8 | -10,877.5 | -15,065.3 |
| EBITDA, % | -150.27 | -18.33 | -55.61 | -38.39 | -10.65 | -44.6 | -44.6 | -44.6 | -44.6 | -44.6 |
| Depreciation | 92.2 | 91.5 | 218.7 | 341.2 | 411.3 | 523.0 | 724.3 | 1,003.2 | 1,389.5 | 1,924.4 |
| Depreciation, % | 8.24 | 2.23 | 4.8 | 7.01 | 6.21 | 5.7 | 5.7 | 5.7 | 5.7 | 5.7 |
| EBIT | -1,773.5 | -844.2 | -2,754.8 | -2,209.6 | -1,117.0 | -4,465.9 | -6,185.3 | -8,566.6 | -11,864.7 | -16,432.6 |
| EBIT, % | -158.51 | -20.56 | -60.41 | -45.4 | -16.85 | -48.64 | -48.64 | -48.64 | -48.64 | -48.64 |
| Total Cash | 5,014.8 | 8,596.0 | 8,481.5 | 8,827.2 | 11,716.4 | 9,180.6 | 12,715.1 | 17,610.4 | 24,390.4 | 33,780.8 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 267.1 | 507.7 | 1,034.3 | 614.4 | 1,074.4 | 1,611.2 | 2,231.5 | 3,090.7 | 4,280.6 | 5,928.6 |
| Account Receivables, % | 23.87 | 12.37 | 22.68 | 12.63 | 16.21 | 17.55 | 17.55 | 17.55 | 17.55 | 17.55 |
| Inventories | 383.0 | 753.7 | 1,439.0 | 1,526.2 | 1,034.0 | 2,407.2 | 3,334.0 | 4,617.6 | 6,395.3 | 8,857.5 |
| Inventories, % | 34.23 | 18.36 | 31.55 | 31.36 | 15.6 | 26.22 | 26.22 | 26.22 | 26.22 | 26.22 |
| Accounts Payable | 90.0 | 128.8 | 208.3 | 347.8 | 397.9 | 530.7 | 735.0 | 1,017.9 | 1,409.8 | 1,952.6 |
| Accounts Payable, % | 8.05 | 3.14 | 4.57 | 7.15 | 6 | 5.78 | 5.78 | 5.78 | 5.78 | 5.78 |
| Capital Expenditure | -390.8 | -824.3 | -1,973.3 | -1,475.8 | -1,477.6 | -2,770.6 | -3,837.2 | -5,314.6 | -7,360.7 | -10,194.6 |
| Capital Expenditure, % | -34.93 | -20.08 | -43.27 | -30.33 | -22.29 | -30.18 | -30.18 | -30.18 | -30.18 | -30.18 |
| Tax Rate, % | 10.18 | 10.18 | 10.18 | 10.18 | 10.18 | 10.18 | 10.18 | 10.18 | 10.18 | 10.18 |
| EBITAT | -1,832.1 | -981.5 | -2,833.4 | -2,218.6 | -1,003.3 | -4,375.0 | -6,059.3 | -8,392.2 | -11,623.2 | -16,098.1 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -2,690.7 | -2,286.9 | -5,720.4 | -2,881.0 | -1,987.3 | -8,399.9 | -10,515.0 | -14,563.3 | -20,170.2 | -27,935.7 |
| WACC, % | 5.06 | 5.06 | 5.06 | 5.06 | 5.04 | 5.06 | 5.06 | 5.06 | 5.06 | 5.06 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -68,469.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -28,494 | |||||||||
| Terminal Value | -932,087 | |||||||||
| Present Terminal Value | -728,334 | |||||||||
| Enterprise Value | -796,803 | |||||||||
| Net Debt | -6,869 | |||||||||
| Equity Value | -789,934 | |||||||||
| Diluted Shares Outstanding, MM | 1,560 | |||||||||
| Equity Value Per Share | -506.49 |
What You Will Receive
- Customizable Forecast Parameters: Modify key assumptions (growth %, margins, WACC) effortlessly to develop various scenarios.
- Comprehensive Market Data: Innovent Biologics, Inc. (1801HK) financial data pre-loaded to facilitate your analysis.
- Automated DCF Calculations: The template computes Net Present Value (NPV) and intrinsic value automatically.
- Professional and Adaptable Design: A refined Excel model tailored to your valuation requirements.
- Designed for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and enhancing efficiency.
Key Features
- Real-Time Innovent Data: Pre-loaded with Innovent Biologics' historical financial performance and future projections.
- Completely Customizable Parameters: Modify variables such as revenue growth, profit margins, discount rates, tax obligations, and capital expenditures.
- Interactive Valuation Framework: Automatically refreshed Net Present Value (NPV) and intrinsic value calculations based on your adjustments.
- Multiple Scenario Analysis: Generate various forecasting scenarios to evaluate different valuation results.
- Intuitive User Interface: Cleanly designed for ease of use, catering to both seasoned professionals and newcomers.
How It Works
- Step 1: Download the Excel template.
- Step 2: Explore Innovent Biologics’ pre-filled financial metrics and projections.
- Step 3: Adjust key variables such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model refresh in real-time as you change inputs.
- Step 5: Review the results and leverage the insights for your investment strategies.
Why Select Innovent Biologics, Inc. (1801HK) Calculator?
- Time-Efficient: Instantly access a DCF model without the hassle of starting from scratch.
- Enhanced Precision: Dependable financial data and formulas minimize valuation errors.
- Fully Adaptable: Customize the model to align with your specific assumptions and forecasts.
- User-Friendly: Intuitive charts and outputs simplify result analysis.
- Recognized by Professionals: Crafted for experts who prioritize accuracy and ease of use.
Who Can Benefit from This Product?
- Investors: Evaluate Innovent Biologics’ (1801HK) valuation prior to making stock trades.
- CFOs and Financial Analysts: Optimize valuation workflows and validate financial forecasts.
- Startup Founders: Understand the valuation methods applied to leading biotech firms like Innovent Biologics (1801HK).
- Consultants: Prepare detailed valuation reports for your clients focused on Innovent Biologics (1801HK).
- Students and Educators: Utilize real-world data to learn and teach effective valuation strategies.
What the Template Includes
- Preloaded 1801HK Data: Historical and projected financial information, encompassing revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Advanced sheets designed for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for modifying revenue growth projections, tax rates, and discount rates.
- Financial Statements: Detailed annual and quarterly financial statements for in-depth analysis.
- Key Ratios: Metrics for profitability, leverage, and efficiency to assess performance.
- Dashboard and Charts: Visual representations of valuation results and underlying assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.